56
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Exelixis's recently active trials. Comparator arms are excluded.
- Zanzalintinib9 trials
- cabozantinib9 trials
- Cabozantinib8 trials
- Nivolumab8 trials
- XL1846 trials
- Atezolizumab5 trials
Upcoming readouts
Next primary completion dates among Exelixis's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
Top therapeutic areas
Conditions studied most often across Exelixis's recently active trials.
- Cancer13 trials
- Colorectal Cancer6 trials
- Renal Cell Carcinoma5 trials
- Prostate Cancer4 trials
- Solid Tumors4 trials
- Castration Resistant Prostate Cancer3 trials
Exelixis pipeline by phase
The main study drugs across 21 active trials Exelixis leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 33 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Zanzalintinib | 7 | 4 | Jan 2027 est. | NCT07750158 · NCT07428616 · NCT06943755 |
| Cabozantinib | 6 | — | May 2030 est. | NCT07620574 · NCT04446117 · NCT03937219 |
| XL092 | 3 | — | Dec 2026 est. | NCT05678673 · NCT05425940 · NCT03845166 |
Phase 14 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| XB010 | 1 | 1 | Nov 2026 est. | NCT06545331 |
| XB371 | 1 | 1 | Nov 2027 est. | NCT07123103 |
| XB628 | 1 | 1 | May 2027 est. | NCT06952010 |
| XL309 | 1 | 1 | Jan 2029 est. | NCT05932862 |
Phase 41 drug
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Cabozantinib (XL184) 140 mg | 1 | — | — | NCT01896479 |
Derived from 21 active trials Exelixis leads; 21 name an intervention, folding into 8 phased drugs. This is ComplyRx's reading of the registry, not Exelixis's own pipeline disclosure.
Exelixis trials
The 50 most significant of Exelixis's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| Study of XB010 in Subjects With Solid TumorsNCT06545331XB010 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 396 est. | 23 Nov 2026 |
| STELLAR-304Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaNCT05678673XL092 | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 317 est. | 15 Dec 2026 |
| STELLAR-002Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483Zanzalintinib | Phase 1 | Locked · track to reveal | OngoingRecruiting | 1,394 est. | 31 Jan 2027 |
| A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid TumorsNCT06952010XB628 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 303 est. | 31 May 2027 |
| A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid TumorsNCT07123103XB371 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 150 est. | Nov 2027 |
| STELLAR-201A Study of Zanzalintinib in Participants With Recurrent or Progressive MeningiomaNCT07428616Zanzalintinib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 100 est. | 29 Feb 2028 |
| Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid TumorsNCT07773454Zanzalintinib | Phase 1 | Not yet scored | OngoingNot yet recruiting | 18 est. | 31 Jul 2028 |
| STELLAR-305Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT06082167Zanzalintinib | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 600 est. | Aug 2028 |
| A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid TumorsNCT05932862XL309 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 429 est. | 3 Jan 2029 |
| STELLAR-311Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsNCT06943755Zanzalintinib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 440 est. | 30 Jun 2029 |
| STELLAR-316Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual DiseaseNCT07750158Zanzalintinib | Phase 3 | Locked · track to reveal | OngoingNot yet recruiting | 600 est. | 5 Apr 2030 |
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574Cabozantinib | Phase 3 | Locked · track to reveal | OngoingEnrolling by invitation | 5,000 est. | 31 May 2030 |
| STELLAR-001A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid TumorsNCT03845166XL092 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 325 est. | 31 Aug 2026 |
| STELLAR-303Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerNCT05425940XL092 | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 901 est. | 16 Jun 2026 |
| Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)NCT06962332Zanzalintinib | Phase 1 | Locked · track to reveal | OngoingRecruiting | 20 est. | Dec 2025 |
| Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)NCT06191796zanzalintinib | Phase 1 | Locked · track to reveal | StoppedTerminated | 25 est. | 12 May 2025 |
| A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid TumorsNCT06630247XL495 | Phase 1 | Locked · track to reveal | StoppedTerminated | 9 est. | 7 May 2025 |
| Study of XB002 in Subjects With Solid Tumors (JEWEL-101)NCT04925284XB002 | Phase 1 | Locked · track to reveal | Completed | 269 est. | 10 Mar 2025 |
| Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)NCT04726332XL102 | Phase 1 | Locked · track to reveal | StoppedTerminated | 52 est. | 2 May 2024 |
| CONTACT-02Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCNCT04446117Cabozantinib | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 575 est. | 19 Apr 2024 |
| Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsNCT03170960cabozantinib | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 914 est. | 21 Feb 2023 |
| Study of XL114 in Subjects With Non-Hodgkin's LymphomaNCT05144347XL114 | Phase 1 | Locked · track to reveal | StoppedTerminated | 2 est. | 1 Nov 2022 |
| COSMIC-313Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell CarcinomaNCT03937219Cabozantinib | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 855 est. | 31 Jan 2022 |
| COSMIC-312Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer TherapyNCT03755791Cabozantinib | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 837 est. | 30 Nov 2021 |
| A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted TherapyNCT03690388Cabozantinib | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 187 est. | 19 Aug 2020 |
| EXAMINERA Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid CancerNCT01896479Cabozantinib (XL184) 140 mg | Phase 4 | Locked · track to reveal | OngoingActive, not recruiting | 247 est. | 15 Jul 2020 |
| CELESTIALStudy of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior SorafenibNCT01908426Cabozantinib tablets | Phase 3 | Locked · track to reveal | Completed | 707 est. | 16 Oct 2017 |
| METEORA Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell CarcinomaNCT01865747Cabozantinib tablets | Phase 3 | Locked · track to reveal | Completed | 658 est. | 22 May 2015 |
| Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced CancerNCT01553656cabozantinib capsules | Phase 1 | Locked · track to reveal | Completed | 85 est. | May 2015 |
| Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPCNCT01995058cabozantinib | Phase 2 | Locked · track to reveal | StoppedTerminated | 54 est. | Nov 2014 |
| COMET-2Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate CancerNCT01522443cabozantinib | Phase 3 | Locked · track to reveal | StoppedTerminated | 119 est. | Oct 2014 |
| COMET-1Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100NCT01605227cabozantinib | Phase 3 | Locked · track to reveal | Completed | 1,028 est. | Sept 2014 |
| Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult SubjectsNCT01493869cabozantinib | Phase 1 | Locked · track to reveal | Completed | 26 est. | May 2014 |
| Study of Cabozantinib (XL184) in Adults With Advanced MalignanciesNCT00940225Cabozantinib | Phase 2 | Locked · track to reveal | Completed | 730 est. | May 2013 |
| A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal FunctionNCT01761773cabozantinib | Phase 1 | Locked · track to reveal | Completed | 32 est. | Apr 2013 |
| Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With GlioblastomaNCT00960492XL184 | Phase 1 | Locked · track to reveal | Completed | 26 est. | Nov 2012 |
| A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid TumorsNCT01100619rosiglitazone | Phase 1 | Locked · track to reveal | Completed | 40 est. | Aug 2012 |
| A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)NCT00596648XL184 | Phase 1 | Locked · track to reveal | Completed | 92 est. | 2 Aug 2012 |
| Study of XL184 (Cabozantinib) in Adults With Glioblastoma MultiformeNCT00704288XL184 | Phase 2 | Locked · track to reveal | Completed | 222 est. | Jun 2012 |
| EXAMEfficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid CancerNCT00704730XL184 | Phase 3 | Locked · track to reveal | Completed | 330 est. | Oct 2011 |
| Study of XL281 in Adults With Solid TumorsNCT00451880XL281 | Phase 1 | Locked · track to reveal | Completed | 180 est. | Oct 2011 |
| Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second RelapseNCT01068782Cabozantinib | Phase 2 | Locked · track to reveal | StoppedTerminated | 19 est. | May 2011 |
| Study of XL184 (Cabozantinib) in Adults With Advanced MalignanciesNCT00215605XL184 | Phase 1 | Locked · track to reveal | Completed | 85 est. | Apr 2011 |
| Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic LeukemiaNCT00464113XL228 | Phase 1 | Locked · track to reveal | StoppedTerminated | 49 est. | Dec 2010 |
| Study of XL228 Administered Intravenously to Subjects With Advanced MalignanciesNCT00526838XL228 | Phase 1 | Locked · track to reveal | StoppedTerminated | 84 est. | Dec 2010 |
| Safety Study of Pharmacokinetics of XL888 in Adults With Solid TumorsNCT00796484XL888 | Phase 1 | Locked · track to reveal | StoppedTerminated | 33 est. | Nov 2010 |
| Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid TumorsNCT00704392XL647 | Phase 1 | Locked · track to reveal | StoppedWithdrawn | 0 est. | Dec 2009 |
| A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or SunitinibNCT00570635XL820 | Phase 2 | Locked · track to reveal | Completed | 16 est. | May 2009 |
| A Phase 1 Study of XL019 in Adults With Polycythemia VeraNCT00595829XL019 | Phase 1 | Locked · track to reveal | StoppedTerminated | 3 est. | Feb 2009 |
| A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced MalignanciesNCT00475917XL844 | Phase 1 | Locked · track to reveal | StoppedTerminated | 28 est. | Dec 2008 |